NAMS NCMP MENOPAUSE EXAM QUESTION BANK
2025/2026 – CERTIFIED MENOPAUSE PRACTITIONER
PRACTICE QUESTIONS, VERIFIED ANSWERS & DETAILED
EXPLANATIONS
This comprehensive exam preparation bundle delivers high-yield multiple-choice
questions, certified answers, and exhaustive clinical explanations modeled after the
official 2025/2026 Menopause Society curriculum. Each practice question targets crucial
exam competencies, including advanced hormone therapy pharmacology, non-
hormonal treatment pathways like neurokinin-3 receptor antagonists, and genitourinary
syndrome of menopause clinical protocols. Designed to mirror the exact rigor of the
Certified Menopause Practitioner (NCMP) credentialing exam, this study resource
bridges complex theoretical knowledge with real-world diagnostic case studies. Medical
professionals and advanced practice nurses will find critical risk-stratification metrics,
timing hypothesis clinical data, and specific drug interaction profiles optimized for rapid
retention. Utilizing this verified question bank ensures deep mastery of foundational
perimenopause management, bone densitometry diagnostics, and strict hormone
therapy contraindications needed for immediate exam day success.
Section 1: Vasomotor Symptoms & Pharmacology
(Questions 1–15)
1. A 52-year-old woman presents with severe,
disrupting nocturnal hot flashes. She had a total
laparoscopic hysterectomy for uterine fibroids three
years ago. She has no contraindications to hormone
therapy. What is the most appropriate first-line
therapy?
A) Continuous combined oral conjugated equine
estrogens and medroxyprogesterone acetate
B) Systemic estrogen therapy alone via transdermal patch
C) Fezolinetant 45 mg orally once daily
D) Paroxetine 7.5 mg orally at bedtime
Rationale: Because the patient has undergone a
,hysterectomy, she does not have an intact uterus and
does not require a progestogen for endometrial
protection. Systemic estrogen therapy alone is the
most effective treatment for moderate-to-severe
vasomotor symptoms (VMS). Transdermal
administration is generally preferred over oral routes
to lower the risk of venous thromboembolism (VTE)
and stroke.
2. A 54-year-old postmenopausal woman with a
history of deep vein thrombosis (DVT) secondary to a
lower extremity fracture 5 years ago requests
treatment for severe vasomotor symptoms. Which
non-hormonal agent is FDA-approved specifically for
moderate-to-severe VMS?
A) Venlafaxine ER 75 mg daily
B) Gabapentin 300 mg at bedtime
C) Paroxetine mesylate 7.5 mg daily
D) Clonidine 0.1 mg daily
Rationale: Paroxetine mesylate (7.5 mg/day) is the
only SSRI formally FDA-approved for the treatment of
moderate-to-severe vasomotor symptoms. While other
SSRIs and SNRIs (like venlafaxine) are highly effective
and widely used off-label, they do not hold the official
FDA approval indicator for VMS. A history of DVT is
an absolute contraindication to systemic hormone
therapy, making non-hormonal agents the primary
choice.
,3. What is the exact primary mechanism of action of
the non-hormonal drug Fezolinetant in alleviating
menopausal hot flashes?
A) Agonism of the serotonin 5-HT2A receptor in the
brainstem
B) Selective antagonism of the neurokinin-3 (NK3)
receptor in the hypothalamus
C) Alpha-2 adrenergic receptor stimulation in the
peripheral vascular bed
D) Modulating the gamma-aminobutyric acid (GABA) A
receptor complex
Rationale: Fezolinetant is a first-in-class, non-
hormonal selective neurokinin-3 (NK3) receptor
antagonist. It blocks neurokinin B binding on the
kisspeptin/neurokinin B/dynorphin (KNDy) neurons
located within the thermoregulatory center of the
hypothalamus, directly correcting the heat-dissipation
hypersensitivity caused by estrogen decline.
4. Before a clinician writes a prescription for
Fezolinetant, which baseline evaluation is explicitly
mandated by the FDA to ensure patient safety?
A) Serum creatinine and calculated glomerular filtration
rate (eGFR)
B) Complete blood count (CBC) with differential
C) Serum alanine aminotransferase (ALT), aspartate
aminotransferase (AST), and total bilirubin
D) Thyroid-stimulating hormone (TSH) and free T4
Rationale: The FDA mandates baseline liver function
, tests (ALT, AST, and total bilirubin) prior to initiating
Fezolinetant due to reported risks of drug-induced
hepatic transaminase elevations. Follow-up liver
function testing must be repeated at months 3, 6, and
9 of active therapy.
5. A 51-year-old woman is taking Tamoxifen as
adjuvant therapy for early-stage estrogen receptor-
positive breast cancer. She experiences severe,
drenching hot flashes. Which antidepressant should
be strictly avoided for VMS management due to a
major drug interaction?
A) Paroxetine
B) Venlafaxine
C) Desvenlafaxine
D) Citalopram
Rationale: Tamoxifen is a prodrug that requires
metabolic activation into its highly potent metabolite,
endoxifen, via the hepatic cytochrome P450 2D6
(CYP2D6) enzyme pathway. Paroxetine (and
fluoxetine) are potent CYP2D6 inhibitors that blunt
this conversion, significantly decreasing tamoxifen
efficacy. Venlafaxine and desvenlafaxine are weak
inhibitors and are safe alternatives.
6. When comparing oral micronized 17β-estradiol to
transdermal 17β-estradiol patches, what unique
physiological consequence occurs exclusively via the
oral route?
A) Dose-dependent downregulation of peripheral
2025/2026 – CERTIFIED MENOPAUSE PRACTITIONER
PRACTICE QUESTIONS, VERIFIED ANSWERS & DETAILED
EXPLANATIONS
This comprehensive exam preparation bundle delivers high-yield multiple-choice
questions, certified answers, and exhaustive clinical explanations modeled after the
official 2025/2026 Menopause Society curriculum. Each practice question targets crucial
exam competencies, including advanced hormone therapy pharmacology, non-
hormonal treatment pathways like neurokinin-3 receptor antagonists, and genitourinary
syndrome of menopause clinical protocols. Designed to mirror the exact rigor of the
Certified Menopause Practitioner (NCMP) credentialing exam, this study resource
bridges complex theoretical knowledge with real-world diagnostic case studies. Medical
professionals and advanced practice nurses will find critical risk-stratification metrics,
timing hypothesis clinical data, and specific drug interaction profiles optimized for rapid
retention. Utilizing this verified question bank ensures deep mastery of foundational
perimenopause management, bone densitometry diagnostics, and strict hormone
therapy contraindications needed for immediate exam day success.
Section 1: Vasomotor Symptoms & Pharmacology
(Questions 1–15)
1. A 52-year-old woman presents with severe,
disrupting nocturnal hot flashes. She had a total
laparoscopic hysterectomy for uterine fibroids three
years ago. She has no contraindications to hormone
therapy. What is the most appropriate first-line
therapy?
A) Continuous combined oral conjugated equine
estrogens and medroxyprogesterone acetate
B) Systemic estrogen therapy alone via transdermal patch
C) Fezolinetant 45 mg orally once daily
D) Paroxetine 7.5 mg orally at bedtime
Rationale: Because the patient has undergone a
,hysterectomy, she does not have an intact uterus and
does not require a progestogen for endometrial
protection. Systemic estrogen therapy alone is the
most effective treatment for moderate-to-severe
vasomotor symptoms (VMS). Transdermal
administration is generally preferred over oral routes
to lower the risk of venous thromboembolism (VTE)
and stroke.
2. A 54-year-old postmenopausal woman with a
history of deep vein thrombosis (DVT) secondary to a
lower extremity fracture 5 years ago requests
treatment for severe vasomotor symptoms. Which
non-hormonal agent is FDA-approved specifically for
moderate-to-severe VMS?
A) Venlafaxine ER 75 mg daily
B) Gabapentin 300 mg at bedtime
C) Paroxetine mesylate 7.5 mg daily
D) Clonidine 0.1 mg daily
Rationale: Paroxetine mesylate (7.5 mg/day) is the
only SSRI formally FDA-approved for the treatment of
moderate-to-severe vasomotor symptoms. While other
SSRIs and SNRIs (like venlafaxine) are highly effective
and widely used off-label, they do not hold the official
FDA approval indicator for VMS. A history of DVT is
an absolute contraindication to systemic hormone
therapy, making non-hormonal agents the primary
choice.
,3. What is the exact primary mechanism of action of
the non-hormonal drug Fezolinetant in alleviating
menopausal hot flashes?
A) Agonism of the serotonin 5-HT2A receptor in the
brainstem
B) Selective antagonism of the neurokinin-3 (NK3)
receptor in the hypothalamus
C) Alpha-2 adrenergic receptor stimulation in the
peripheral vascular bed
D) Modulating the gamma-aminobutyric acid (GABA) A
receptor complex
Rationale: Fezolinetant is a first-in-class, non-
hormonal selective neurokinin-3 (NK3) receptor
antagonist. It blocks neurokinin B binding on the
kisspeptin/neurokinin B/dynorphin (KNDy) neurons
located within the thermoregulatory center of the
hypothalamus, directly correcting the heat-dissipation
hypersensitivity caused by estrogen decline.
4. Before a clinician writes a prescription for
Fezolinetant, which baseline evaluation is explicitly
mandated by the FDA to ensure patient safety?
A) Serum creatinine and calculated glomerular filtration
rate (eGFR)
B) Complete blood count (CBC) with differential
C) Serum alanine aminotransferase (ALT), aspartate
aminotransferase (AST), and total bilirubin
D) Thyroid-stimulating hormone (TSH) and free T4
Rationale: The FDA mandates baseline liver function
, tests (ALT, AST, and total bilirubin) prior to initiating
Fezolinetant due to reported risks of drug-induced
hepatic transaminase elevations. Follow-up liver
function testing must be repeated at months 3, 6, and
9 of active therapy.
5. A 51-year-old woman is taking Tamoxifen as
adjuvant therapy for early-stage estrogen receptor-
positive breast cancer. She experiences severe,
drenching hot flashes. Which antidepressant should
be strictly avoided for VMS management due to a
major drug interaction?
A) Paroxetine
B) Venlafaxine
C) Desvenlafaxine
D) Citalopram
Rationale: Tamoxifen is a prodrug that requires
metabolic activation into its highly potent metabolite,
endoxifen, via the hepatic cytochrome P450 2D6
(CYP2D6) enzyme pathway. Paroxetine (and
fluoxetine) are potent CYP2D6 inhibitors that blunt
this conversion, significantly decreasing tamoxifen
efficacy. Venlafaxine and desvenlafaxine are weak
inhibitors and are safe alternatives.
6. When comparing oral micronized 17β-estradiol to
transdermal 17β-estradiol patches, what unique
physiological consequence occurs exclusively via the
oral route?
A) Dose-dependent downregulation of peripheral
